Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Propranolol for Early Retinopathy of Prematurity
NCT02977000Unknown
- Start
- May 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of propranolol in retinopathy of prematurity (ROP) (2 arms). Primary endpoint: Rates of regression of Retinopathy of Prematurity at 2 years. Status: unknown.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02977000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977000.